Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
NEW YORK, Jan. 08, 2018 -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. The presentation is scheduled to take place on Thursday, January 11, 2018 at 7:30am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
CONTACT:
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]
